학술논문
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
Document Type
Author
Stevens, Kate I.; Frangou, Eleni; Shin, Jae Il; Anders, Hans Joachim; Bruchfeld, Annette; Schönermarck, Ulf; Hauser, Thomas; Westman, Kerstin; Fernandez-Juarez, Gema M.; Floege, Jürgen; Goumenos, Dimitrios; Turkmen, Kultigin; van Kooten, Cees; McAdoo, Stephen P.; Tesar, Vladimir; Segelmark, Mårten; Geetha, Duvuru; Jayne, David R.W.; Kronbichler, Andreas
Source
Nephrology Dialysis Transplantation. 37(8):1400-1410
Subject
Language
English
ISSN
0931-0509
Abstract
Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.